메뉴 건너뛰기




Volumn 31, Issue SUPPL.76, 2013, Pages

The significance of interleukin-6 and C-reactive protein in systemic sclerosis: A systematic literature review

Author keywords

C reactive protein; Interleukin 6; Scleroderma; Systematic review; Systemic sclerosis

Indexed keywords

ATORVASTATIN; BOSENTAN; C REACTIVE PROTEIN; COLLAGEN TYPE 5; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ILOPROST; INTERLEUKIN 6; NORPHENAZONE; PLACEBO; PREDNISONE; PROSTAGLANDIN E1; RAPAMYCIN; RITUXIMAB; SIMVASTATIN; TOCILIZUMAB; IL6 PROTEIN, HUMAN;

EID: 84883774149     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (46)

References (202)
  • 1
    • 84857042496 scopus 로고    scopus 로고
    • Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts
    • RABQUER BJ, KOCH AE: Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts. Curr Rheumatol Rep 2012; 14: 56-63.
    • (2012) Curr Rheumatol Rep , vol.14 , pp. 56-63
    • Rabquer, B.J.1    Koch, A.E.2
  • 4
    • 0038799783 scopus 로고    scopus 로고
    • Scleroderma epidemiology
    • MAYES M: Scleroderma epidemiology. Rheum Dis Clin N Am 2003; 29: 239-54.
    • (2003) Rheum Dis Clin N Am , vol.29 , pp. 239-254
    • Mayes, M.1
  • 5
    • 0023854176 scopus 로고
    • Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis
    • LeROY EC, BLACK C, FLEISCHMAJER R et al.: Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988; 15: 202-5.
    • (1988) J Rheumatol , vol.15 , pp. 202-205
    • Leroy, E.C.1    Black, C.2    Fleischmajer, R.3
  • 6
    • 74449087538 scopus 로고    scopus 로고
    • Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital
    • JOVEN BE, ALMODOVAR R, CARMONA L, CARREIRA PE: Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital. Semin Arthritis Rheum 2010; 39: 285-93.
    • (2010) Semin Arthritis Rheum , vol.39 , pp. 285-293
    • Joven, B.E.1    Almodovar, R.2    Carmona, L.3    Carreira, P.E.4
  • 7
    • 74449085877 scopus 로고    scopus 로고
    • Determinants of morbidity and mortality of systemic sclerosis in Canada
    • Al-DHAHER FF, POPE JE, OUIMET JM: Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010; 39: 269-77.
    • (2010) Semin Arthritis Rheum , vol.39 , pp. 269-277
    • Al-Dhaher, F.F.1    Pope, J.E.2    Ouimet, J.M.3
  • 11
    • 0038799783 scopus 로고    scopus 로고
    • Scleroderma epidemiology
    • MAYES M: Scleroderma epidemiology. Rheum Dis Clin N Am 2003; 29: 239-54.
    • (2003) Rheum Dis Clin N Am , vol.29 , pp. 239-254
    • Mayes, M.1
  • 12
    • 0023854176 scopus 로고
    • Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis
    • LeROY EC, BLACK C, FLEISCHMAJER R et al.: Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988; 15: 202-5.
    • (1988) J Rheumatol , vol.15 , pp. 202-205
    • Leroy, E.C.1    Black, C.2    Fleischmajer, R.3
  • 13
    • 74449087538 scopus 로고    scopus 로고
    • Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital
    • JOVEN BE, ALMODOVAR R, CARMONA L, CARREIRA PE: Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital. Semin Arthritis Rheum 2010; 39: 285-93.
    • (2010) Semin Arthritis Rheum , vol.39 , pp. 285-293
    • Joven, B.E.1    Almodovar, R.2    Carmona, L.3    Carreira, P.E.4
  • 14
    • 74449085877 scopus 로고    scopus 로고
    • Determinants of morbidity and mortality of systemic sclerosis in Canada
    • Al-DHAHER FF, POPE JE, OUIMET JM: Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010; 39: 269-77.
    • (2010) Semin Arthritis Rheum , vol.39 , pp. 269-277
    • Al-Dhaher, F.F.1    Pope, J.E.2    Ouimet, J.M.3
  • 15
    • 0031855190 scopus 로고    scopus 로고
    • Mortality and causes of death of 344 Dan ish patients with systemic sclerosis (scleroderma)
    • JACOBSEN S, HALBERG P, ULLMAN S: Mortality and causes of death of 344 Dan ish patients with systemic sclerosis (scleroderma). Br J Rheumatol 1998; 37: 750-5.
    • (1998) Br J Rheumatol , vol.37 , pp. 750-755
    • Jacobsen, S.1    Halberg, P.2    Ullman, S.3
  • 16
    • 37749017657 scopus 로고    scopus 로고
    • Survival and causes of death in 366 Hungarian patients with systemic sclerosis
    • CZIRJÁK L, KUMÁNOVICS G, VARJú C et al.: Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008; 67: 59-63.
    • (2008) Ann Rheum Dis , vol.67 , pp. 59-63
    • Czirják, L.1    Kumánovics, G.2    Varjú, C.3
  • 17
    • 78650415467 scopus 로고    scopus 로고
    • Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis
    • BARAUT J, MICHEL L, VERRECCHIA F, FARGE D: Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun Rev 2010; 10: 65-73.
    • (2010) Autoimmun Rev , vol.10 , pp. 65-73
    • Baraut, J.1    Michel, L.2    Verrecchia, F.3    Farge, D.4
  • 18
    • 84859438199 scopus 로고    scopus 로고
    • The pathogenesis of rheumatoid arthritis: new insights from old clinical data?
    • SMOLEN JS, ALETAHA D, REDLICH K: The pathogenesis of rheumatoid arthritis: new insights from old clinical data?. Nat Rev Rheumatol 2012; 8: 235-43.
    • (2012) Nat Rev Rheumatol , vol.8 , pp. 235-243
    • Smolen, J.S.1    Aletaha, D.2    Redlich, K.3
  • 19
    • 84878134773 scopus 로고    scopus 로고
    • Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage
    • ABDEL MEGUID MH, HAMAD YH, SWILAM RS, BARAKAT MS: Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage. Rheumatol Int 2013; 33: 697-703.
    • (2013) Rheumatol Int , vol.33 , pp. 697-703
    • Abdel Meguid, M.H.1    Hamad, Y.H.2    Swilam, R.S.3    Barakat, M.S.4
  • 20
    • 84864481289 scopus 로고    scopus 로고
    • Brief Report: Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis
    • SAMSON M, AUDIA S, JANIKASHVILI N et al.: Brief Report: Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64: 2499-503.
    • (2012) Arthritis Rheum , vol.64 , pp. 2499-2503
    • Samson, M.1    Audia, S.2    Janikashvili, N.3
  • 21
    • 84859624578 scopus 로고    scopus 로고
    • Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting theinterleukin-6 receptor
    • NAVARRO-MILLÁN I, SINGH JA, CURTIS JR: Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting theinterleukin-6 receptor. Clin Ther 2012; 34: 788-802.
    • (2012) Clin Ther , vol.34 , pp. 788-802
    • Navarro-Millán, I.1    Singh, J.A.2    Curtis, J.R.3
  • 22
    • 0042744797 scopus 로고    scopus 로고
    • C-reactive protein: a critical update
    • PEPYS MB, HIRSCHFIELD GM: C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-12.
    • (2003) J Clin Invest , vol.111 , pp. 1805-1812
    • Pepys, M.B.1    Hirschfield, G.M.2
  • 23
    • 0027159417 scopus 로고
    • Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis
    • GABAY C, ROUX-LOMBARD P, de MOERLOOSE P, DAYER JM, VISCHER T, GUERNE PA: Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis. J Rheumatol 1993; 20: 815-21.
    • (1993) J Rheumatol , vol.20 , pp. 815-821
    • Gabay, C.1    Roux-Lombard, P.2    de Moerloose, P.3    Dayer, J.M.4    Vischer, T.5    Guerne, P.A.6
  • 24
    • 34250166546 scopus 로고    scopus 로고
    • Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis
    • EMERY P, GABAY C, KRAAN M, GOMEZREINO J: Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int 2007; 27: 793-806.
    • (2007) Rheumatol Int , vol.27 , pp. 793-806
    • Emery, P.1    Gabay, C.2    Kraan, M.3    Gomezreino, J.4
  • 25
    • 79956159584 scopus 로고    scopus 로고
    • Highsensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus
    • FIROOZ N, ALBERT DA, WALLACE DJ, ISHIMORI M, BEREL D, WEISMAN MH: Highsensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. Lupus 2011; 20: 588-97.
    • (2011) Lupus , vol.20 , pp. 588-597
    • Firooz, N.1    Albert, D.A.2    Wallace, D.J.3    Ishimori, M.4    Berel, D.5    Weisman, M.H.6
  • 26
    • 84861805021 scopus 로고    scopus 로고
    • Interleukin 6 in systemic sclerosis and potential implications for targeted therapy
    • MUANGCHAN C, POPE JE: Interleukin 6 in systemic sclerosis and potential implications for targeted therapy. J Rheumatol 2012; 39: 1120-4.
    • (2012) J Rheumatol , vol.39 , pp. 1120-1124
    • Muangchan, C.1    Pope, J.E.2
  • 27
    • 84865593221 scopus 로고    scopus 로고
    • C - reactive protein (CRP) is associated with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG)
    • MUANGCHAN C, HARDING S, KHIMDAS S, BONNER A, BARON M, POPE J; the Canadian Scleroderma Research Group (CSRG): C - reactive protein (CRP) is associated with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG). Arthritis Care Res (Hoboken) 2012; 64: 1405-14.
    • (2012) Arthritis Care Res (Hoboken) , vol.64 , pp. 1405-1414
    • Muangchan, C.1    Harding, S.2    Khimdas, S.3    Bonner, A.4    Baron, M.5    Pope, J.6
  • 28
    • 73249149749 scopus 로고    scopus 로고
    • Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: Evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines
    • GOURH P, AGARWAL SK, DIVECHA D et al.: Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: Evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. Arthritis Rheum 2009; 60: 3794-806.
    • (2009) Arthritis Rheum , vol.60 , pp. 3794-3806
    • Gourh, P.1    Agarwal, S.K.2    Divecha, D.3
  • 29
    • 47249132572 scopus 로고    scopus 로고
    • Ability of epistatic interactions of cytokine singlenucleotide polymorphisms to predict susceptibility to disease subsets in systemic sclerosis patients
    • BERETTA L, CAPPIELLO F, MOORE JH, BARILI M, GREENE CS, SCORZA R: Ability of epistatic interactions of cytokine singlenucleotide polymorphisms to predict susceptibility to disease subsets in systemic sclerosis patients. Arthritis Care Res 2008; 59: 974-83.
    • (2008) Arthritis Care Res , vol.59 , pp. 974-983
    • Beretta, L.1    Cappiello, F.2    Moore, J.H.3    Barili, M.4    Greene, C.S.5    Scorza, R.6
  • 30
    • 84867200145 scopus 로고    scopus 로고
    • The IL-6 promoter polymorphism is associated with disease activity and disability in systemic sclerosis
    • SFRENT-CORNATEANU R, MIHAI C, BALAN S, IONESCU R, MOLDOVEANU E: The IL-6 promoter polymorphism is associated with disease activity and disability in systemic sclerosis. J Cell Mol Med 2006; 10: 955-9.
    • (2006) J Cell Mol Med , vol.10 , pp. 955-959
    • Sfrent-Cornateanu, R.1    Mihai, C.2    Balan, S.3    Ionescu, R.4    Moldoveanu, E.5
  • 31
    • 84855281875 scopus 로고    scopus 로고
    • A rare polymorphism in the gene for toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators
    • BROEN JCA, BOSSINI-CASTILLO L, Van BON L et al.: A rare polymorphism in the gene for toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators. Arthritis Rheum 2012; 64: 264-71.
    • (2012) Arthritis Rheum , vol.64 , pp. 264-271
    • Broen, J.C.A.1    Bossini-Castillo, L.2    Van Bon, L.3
  • 32
    • 84870315000 scopus 로고    scopus 로고
    • Influence of the IL6 gene in susceptibility to systemic sclerosis
    • CNIT MC, SIMEóN CP, VONK MC et al.: Influence of the IL6 gene in susceptibility to systemic sclerosis. J Rheumatol 2012; 39: 2294-302.
    • (2012) J Rheumatol , vol.39 , pp. 2294-2302
    • Cénit, M.C.1    Simeón, C.P.2    Vonk, M.C.3
  • 33
    • 84864823236 scopus 로고    scopus 로고
    • No evidence of association between functional polymorphisms located within IL6R and IL6ST genes and systemic sclerosis
    • CÉNIT MC, SIMEóN CP, FONOLLOSA V et al.; Spanish Scleroderma Group: No evidence of association between functional polymorphisms located within IL6R and IL6ST genes and systemic sclerosis. Tissue Antigens 2012; 80: 254-8.
    • (2012) Tissue Antigens , vol.80 , pp. 254-258
    • Cénit, M.C.1    Simeón, C.P.2    Fonollosa, V.3
  • 34
    • 84884935041 scopus 로고    scopus 로고
    • Association study of CRP gene in systemic sclerosis in European Caucasian population
    • 2013 Feb. 9 [Epub ahead of print]
    • WIPFF J, DIEUDÉ P, AVOUAC J et al.: Association study of CRP gene in systemic sclerosis in European Caucasian population. 2013 Feb. 9 [Epub ahead of print].
    • Wipff, J.1    Dieudé, P.2    Avouac, J.3
  • 35
    • 83455230778 scopus 로고    scopus 로고
    • Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma
    • KITABA S, MUROTA H, TERAO M et al.: Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 2012; 180: 165-76.
    • (2012) Am J Pathol , vol.180 , pp. 165-176
    • Kitaba, S.1    Murota, H.2    Terao, M.3
  • 36
    • 80155206307 scopus 로고    scopus 로고
    • Immunization with DNA topoisomerase 1 and freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling
    • YOSHIZAKI A, YANABA K, OGAWA A, ASANO Y, KADONO T, SATO S: Immunization with DNA topoisomerase 1 and freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis Rheum 2011; 63: 3575-85.
    • (2011) Arthritis Rheum , vol.63 , pp. 3575-3585
    • Yoshizaki, A.1    Yanaba, K.2    Ogawa, A.3    Asano, Y.4    Kadono, T.5    Sato, S.6
  • 37
    • 78751701215 scopus 로고    scopus 로고
    • Allograft inflammatory factor-1 is over expressed and induces fibroblast chemotaxis in the skin of sclerodermatous GVHD in a murine model
    • YAMAMOTO A, ASHIHARA E, NAKAGAWA Y et al.: Allograft inflammatory factor-1 is over expressed and induces fibroblast chemotaxis in the skin of sclerodermatous GVHD in a murine model. Immunol Lett 2011; 135: 144-50.
    • (2011) Immunol Lett , vol.135 , pp. 144-150
    • Yamamoto, A.1    Ashihara, E.2    Nakagawa, Y.3
  • 38
    • 84870516776 scopus 로고    scopus 로고
    • IL-6 blockade attenuates the development of murine sclerodermatous chronic graftversus- host disease
    • Le HUU D, MATSUSHITA T, JIN G et al.: IL-6 blockade attenuates the development of murine sclerodermatous chronic graftversus- host disease. J Invest Dermatol 2012; 132: 2752-61.
    • (2012) J Invest Dermatol , vol.132 , pp. 2752-2761
    • Le Huu, D.1    Matsushita, T.2    Jin, G.3
  • 39
    • 0032739412 scopus 로고    scopus 로고
    • CD19 is a central response regulator of B lymphocyte signaling thresholds governing autoimmunity
    • SATO S: CD19 is a central response regulator of B lymphocyte signaling thresholds governing autoimmunity. J Dermatol Sci 1999; 22: 1-10.
    • (1999) J Dermatol Sci , vol.22 , pp. 1-10
    • Sato, S.1
  • 40
    • 16544364829 scopus 로고    scopus 로고
    • The CD19-CD21 signal transduction complex of B lymphocytes regulates the balance between health and autoimmune disease: systemic sclerosis as a model system
    • TEDDER TF, POE JC, FUJIMOTO M, HAAS KM, SATO S: The CD19-CD21 signal transduction complex of B lymphocytes regulates the balance between health and autoimmune disease: systemic sclerosis as a model system. Curr Dir Autoimmun 2005; 8: 55-90.
    • (2005) Curr Dir Autoimmun , vol.8 , pp. 55-90
    • Tedder, T.F.1    Poe, J.C.2    Fujimoto, M.3    Haas, K.M.4    Sato, S.5
  • 41
    • 78649835509 scopus 로고    scopus 로고
    • Targeting BAFF in autoimmunity
    • DAVIDSON A: Targeting BAFF in autoimmunity. Curr Opin Immunol 2010; 22: 732-9.
    • (2010) Curr Opin Immunol , vol.22 , pp. 732-739
    • Davidson, A.1
  • 42
    • 70349658717 scopus 로고    scopus 로고
    • BAFF: a local and systemic target in autoimmune diseases
    • MOISINI I, DAVIDSON A: BAFF: a local and systemic target in autoimmune diseases. Clin Exp Immunol 2009; 158: 155-63.
    • (2009) Clin Exp Immunol , vol.158 , pp. 155-163
    • Moisini, I.1    Davidson, A.2
  • 43
    • 34247574625 scopus 로고    scopus 로고
    • B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling
    • MACKAY F, SILVEIRA PA, BRINK R: B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 2007; 19: 327-36.
    • (2007) Curr Opin Immunol , vol.19 , pp. 327-336
    • Mackay, F.1    Silveira, P.A.2    Brink, R.3
  • 44
    • 44849130732 scopus 로고    scopus 로고
    • CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma
    • YOSHIZAKI A, IWATA Y, KOMURA K et al.: CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 2008; 172: 1650-63.
    • (2008) Am J Pathol , vol.172 , pp. 1650-1663
    • Yoshizaki, A.1    Iwata, Y.2    Komura, K.3
  • 45
    • 0036262665 scopus 로고    scopus 로고
    • CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse
    • SAITO E, FUJIMOTO M, HASEGAWA M et al.: CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002; 109: 1453-62.
    • (2002) J Clin Invest , vol.109 , pp. 1453-1462
    • Saito, E.1    Fujimoto, M.2    Hasegawa, M.3
  • 46
    • 36248941233 scopus 로고    scopus 로고
    • BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice
    • MATSUSHITA T, FUJIMOTO M, HASEGAWA M et al.: BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice. J Invest Dermatol 2007; 127: 2772- 80.
    • (2007) J Invest Dermatol , vol.127
    • Matsushita, T.1    Fujimoto, M.2    Hasegawa, M.3
  • 47
    • 0034468138 scopus 로고    scopus 로고
    • Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation
    • ORTMANN RA, CHENG T, VISCONTI R, FRUCHT DM, O'SHEA JJ: Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation. Arthritis Res 2000; 2: 16-32.
    • (2000) Arthritis Res , vol.2 , pp. 16-32
    • Ortmann, R.A.1    Cheng, T.2    Visconti, R.3    Frucht, D.M.4    O'shea, J.J.5
  • 48
    • 84859972127 scopus 로고    scopus 로고
    • JAK and STAT signaling molecules in immunoregulation and immune-mediated disease
    • O'SHEA JJ, PLENGE R: JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 2012; 36: 542-50.
    • (2012) Immunity , vol.36 , pp. 542-550
    • O'sHea, J.J.1    Plenge, R.2
  • 50
    • 84555205600 scopus 로고    scopus 로고
    • IL-6/IL-6 receptor system and its role in physiological and pathological conditions
    • MIHARA M, HASHIZUME M, YOSHIDA H, SUZUKI M, SHIINA M: IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 2012; 122: 143-59.
    • (2012) Clin Sci (Lond) , vol.122 , pp. 143-159
    • Mihara, M.1    Hashizume, M.2    Yoshida, H.3    Suzuki, M.4    Shiina, M.5
  • 51
    • 79953676584 scopus 로고    scopus 로고
    • Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis
    • AVOUAC J, FüRNROHR BG, TOMCIK M et al.: Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum 2011; 63: 800-9.
    • (2011) Arthritis Rheum , vol.63 , pp. 800-809
    • Avouac, J.1    Fürnrohr, B.G.2    Tomcik, M.3
  • 53
    • 77952943759 scopus 로고    scopus 로고
    • Inducible co stimulator ligand regulates bleomycin- induced lung and skin fibrosis in a mouse model independently of the inducible co stimulator/inducible co stimulator ligand pathway
    • TANAKA C, FUJIMOTO M, HAMAGUCHI Y, SATO S, TAKEHARA K, HASEGAWA M: Inducible co stimulator ligand regulates bleomycin- induced lung and skin fibrosis in a mouse model independently of the inducible co stimulator/inducible co stimulator ligand pathway. Arthritis Rheum 2010; 62: 1723- 32.
    • (2010) Arthritis Rheum , vol.62
    • Tanaka, C.1    Fujimoto, M.2    Hamaguchi, Y.3    Sato, S.4    Takehara, K.5    Hasegawa, M.6
  • 54
    • 80053495041 scopus 로고    scopus 로고
    • The specific free radical scavenger edaravone suppresses fibrosis in the bleomycininduced and tight skin mouse models of systemic sclerosis
    • YOSHIZAKI A, YANABA K, OGAWA A et al.: The specific free radical scavenger edaravone suppresses fibrosis in the bleomycininduced and tight skin mouse models of systemic sclerosis. Arthritis Rheum 2011; 63: 3086-97.
    • (2011) Arthritis Rheum , vol.63 , pp. 3086-3097
    • Yoshizaki, A.1    Yanaba, K.2    Ogawa, A.3
  • 55
    • 77955349716 scopus 로고    scopus 로고
    • Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis
    • YOSHIZAKI A, YANABA K, YOSHIZAKI A et al.: Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum 2010; 62: 2476-87.
    • (2010) Arthritis Rheum , vol.62 , pp. 2476-2487
    • Yoshizaki, A.1    Yanaba, K.2    Yoshizaki, A.3
  • 56
    • 73249139173 scopus 로고    scopus 로고
    • Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized single-blind pilot study
    • SU TI, KHANNA D, FURST DE et al.: Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized single-blind pilot study. Arthritis Rheum 2009; 60: 3821-30.
    • (2009) Arthritis Rheum , vol.60 , pp. 3821-3830
    • Su, T.I.1    Khanna, D.2    Furst, D.E.3
  • 57
    • 77955708579 scopus 로고    scopus 로고
    • Inhibition of bleomycin-induced pulmonary fibrosis through pre-treatment with collagen type V
    • BRAUN RK, MARTIN A, SHAH S et al.: Inhibition of bleomycin-induced pulmonary fibrosis through pre-treatment with collagen type V. J Heart Lung Transplant 2010; 29: 873-80.
    • (2010) J Heart Lung Transplant , vol.29 , pp. 873-880
    • Braun, R.K.1    Martin, A.2    Shah, S.3
  • 58
    • 45349109299 scopus 로고    scopus 로고
    • A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in latephase disease
    • POSTLETHWAITE AE, WONG WK, CLEMENTS P et al.: A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in latephase disease. Arthritis Rheum 2008; 58: 1810-22.
    • (2008) Arthritis Rheum , vol.58 , pp. 1810-1822
    • Postlethwaite, A.E.1    Wong, W.K.2    Clements, P.3
  • 59
    • 0033017344 scopus 로고    scopus 로고
    • Anti-sclerotic effect of transforming growth factor-ß antibody in a mouse model of bleomycin-induced scleroderma
    • YAMAMOTO T, TAKAGAWA S, KATAYAMA I, NISHIOKA K: Anti-sclerotic effect of transforming growth factor-ß antibody in a mouse model of bleomycin-induced scleroderma. Clinical Immunology 1999; 92: 6-13.
    • (1999) Clinical Immunology , vol.92 , pp. 6-13
    • Yamamoto, T.1    Takagawa, S.2    Katayama, I.3    Nishioka, K.4
  • 60
    • 33846250366 scopus 로고    scopus 로고
    • Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT- 192
    • DENTON CP, MERKEL PA, FURST DE et al.: Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT- 192. Arthritis Rheum 2007; 56: 323-33.
    • (2007) Arthritis Rheum , vol.56 , pp. 323-333
    • Denton, C.P.1    Merkel, P.A.2    Furst, D.E.3
  • 61
    • 84860734406 scopus 로고    scopus 로고
    • Systemic sclerosis fibroblasts show specific alterations of interferon-? and tumor necrosis factor-a-induced modulation of interleukin 6 and chemokine ligand 2
    • ANTONELLI A, FALLAHI P, FERRARI SM et al.: Systemic sclerosis fibroblasts show specific alterations of interferon-? and tumor necrosis factor-a-induced modulation of interleukin 6 and chemokine ligand 2. J Rheumatol 2012; 39: 979-85.
    • (2012) J Rheumatol , vol.39 , pp. 979-985
    • Antonelli, A.1    Fallahi, P.2    Ferrari, S.M.3
  • 62
    • 84862520877 scopus 로고    scopus 로고
    • Clinical and pathological significance of interleukin 6 over expression in systemic sclerosis
    • KHAN K, XU S, NIHTYANOVA S et al.: Clinical and pathological significance of interleukin 6 over expression in systemic sclerosis. Ann Rheum Dis 2012; 71: 1235-42.
    • (2012) Ann Rheum Dis , vol.71 , pp. 1235-1242
    • Khan, K.1    Xu, S.2    Nihtyanova, S.3
  • 63
    • 83455210338 scopus 로고    scopus 로고
    • IFN-γ and TNF-a induce a different modulation of interleukin-6 in systemic sclerosis fibroblasts compared to healthy controls
    • ANTONELLI A, FERRI C, FERRARI SM et al.: IFN-γ and TNF-a induce a different modulation of interleukin-6 in systemic sclerosis fibroblasts compared to healthy controls. Scand J Rheumatol 2011; 40: 453-6.
    • (2011) Scand J Rheumatol , vol.40 , pp. 453-456
    • Antonelli, A.1    Ferri, C.2    Ferrari, S.M.3
  • 64
    • 77954222254 scopus 로고    scopus 로고
    • Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: Is T-cell response aimed to play a protective role?
    • De PALMA R, D'AIUTO E, VETTORI S, CUOPPOLO P, ABBATE G, VALENTINI G: Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: Is T-cell response aimed to play a protective role?. Rheumatology 2010; 49: 1257-66.
    • (2010) Rheumatology , vol.49 , pp. 1257-1266
    • De Palma, R.1    D'aiuto, E.2    Vettori, S.3    Cuoppolo, P.4    Abbate, G.5    Valentini, G.6
  • 65
    • 70349785531 scopus 로고    scopus 로고
    • Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts
    • GARCIA-GONZALEZ E, SELVI E, BALISTRERI E et al.: Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts. Rheumatology 2009; 48: 1050-6.
    • (2009) Rheumatology , vol.48 , pp. 1050-1056
    • Garcia-Gonzalez, E.1    Selvi, E.2    Balistreri, E.3
  • 66
    • 0031935542 scopus 로고    scopus 로고
    • Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts
    • KADONO T, KIKUCHI K, IHN H, TAKEHARA K, TAMAKI K: Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol 1998; 25: 296-301.
    • (1998) J Rheumatol , vol.25 , pp. 296-301
    • Kadono, T.1    Kikuchi, K.2    Ihn, H.3    Takehara, K.4    Tamaki, K.5
  • 67
    • 0026767273 scopus 로고
    • Mechanisms of pathogenesis in scleroderma. I. overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma
    • FEGHALI CA, BOST KL, BOULWARE DW, LEVY LS: Mechanisms of pathogenesis in scleroderma. I. overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol 1992; 19: 1207-11.
    • (1992) J Rheumatol , vol.19 , pp. 1207-1211
    • Feghali, C.A.1    Bost, K.L.2    Boulware, D.W.3    Levy, L.S.4
  • 68
    • 0032011592 scopus 로고    scopus 로고
    • Spontaneous cytokine gene expression by cultured skin fibroblasts of systemic sclerosis. correlation with collagen synthesis
    • ZURITA-SALINAS CS, RICHAUD-PATIN Y, KRöTZSCH-GóMEZ E et al.: Spontaneous cytokine gene expression by cultured skin fibroblasts of systemic sclerosis. correlation with collagen synthesis. Revista de Investigacion Clinica 1998; 50: 97-104.
    • (1998) Revista de Investigacion Clinica , vol.50 , pp. 97-104
    • Zurita-Salinas, C.S.1    Richaud-Patin, Y.2    Krötzsch-Gómez, E.3
  • 69
    • 0027933282 scopus 로고
    • Control of IL-6 expression and response in fibroblasts from patients with systemic sclerosis
    • FEGHALI CA, BOST KL, BOULWARE DW, LEVY LS: Control of IL-6 expression and response in fibroblasts from patients with systemic sclerosis. Autoimmunity 1994; 17: 309-18.
    • (1994) Autoimmunity , vol.17 , pp. 309-318
    • Feghali, C.A.1    Bost, K.L.2    Boulware, D.W.3    Levy, L.S.4
  • 70
    • 0027976645 scopus 로고
    • Immunologic parameters in systemic sclerosis
    • BRUNS M, HERRMANN K, HAUSTEIN U-: Immunologic parameters in systemic sclerosis. Int J Dermatol 1994; 33: 25-32.
    • (1994) Int J Dermatol , vol.33 , pp. 25-32
    • Bruns, M.1    Herrmann, K.2    Haustein, U.3
  • 71
    • 0035925040 scopus 로고    scopus 로고
    • Establishment and characterization of a human B cell line from the lung tissue of a patient with scleroderma; extraordinary high level of IL-6 secretion by stimulated fibroblasts
    • KONDO K, OKADA T, MATSUI T et al.: Establishment and characterization of a human B cell line from the lung tissue of a patient with scleroderma; extraordinary high level of IL-6 secretion by stimulated fibroblasts. Cytokine 2001; 13: 220-6.
    • (2001) Cytokine , vol.13 , pp. 220-226
    • Kondo, K.1    Okada, T.2    Matsui, T.3
  • 72
    • 33749243490 scopus 로고    scopus 로고
    • Intracellular IL-1a-binding proteins contribute to biological functions of endogenous IL-1a in systemic sclerosis fibroblasts
    • KAWAGUCHI Y, NISHIMAGI E, TOCHIMOTO A et al.: Intracellular IL-1a-binding proteins contribute to biological functions of endogenous IL-1a in systemic sclerosis fibroblasts. Proc Natl Acad Sci USA 2006; 103: 14501-6.
    • (2006) Proc Natl Acad Sci USA , vol.103 , pp. 14501-14506
    • Kawaguchi, Y.1    Nishimagi, E.2    Tochimoto, A.3
  • 73
    • 5044232255 scopus 로고    scopus 로고
    • Autocrine activation by interleukin 1a induces the fibrogenic phenotype of systemic sclerosis fibroblasts
    • KAWAGUCHI Y, McCARTHY SA, WATKINS SC, WRIGHT TM: Autocrine activation by interleukin 1a induces the fibrogenic phenotype of systemic sclerosis fibroblasts. J Rheumatol 2004; 31: 1946-54.
    • (2004) J Rheumatol , vol.31 , pp. 1946-1954
    • Kawaguchi, Y.1    Mccarthy, S.A.2    Watkins, S.C.3    Wright, T.M.4
  • 74
    • 0036269002 scopus 로고    scopus 로고
    • Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis
    • CHIZZOLINI C, RASCHI E, REZZONICO R et al.: Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 2002; 46: 1602-13.
    • (2002) Arthritis Rheum , vol.46 , pp. 1602-1613
    • Chizzolini, C.1    Raschi, E.2    Rezzonico, R.3
  • 75
    • 0033121274 scopus 로고    scopus 로고
    • Endogenous IL-1a from systemic sclerosis fibroblasts induces IL-6 and PDGF-A
    • KAWAGUCHI Y, HARA M, WRIGHT TM: Endogenous IL-1a from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999; 103: 1253-60.
    • (1999) J Clin Invest , vol.103 , pp. 1253-1260
    • Kawaguchi, Y.1    Hara, M.2    Wright, T.M.3
  • 76
    • 0027280170 scopus 로고
    • Interleukin 1 receptor on fibroblasts from systemic sclerosis patients induces excessive functional responses to interleukin 1ß
    • KAWAGUCHI Y, HARIGAI M, SUZUKI K et al.: Interleukin 1 receptor on fibroblasts from systemic sclerosis patients induces excessive functional responses to interleukin 1ß. Biochem Biophys Res Commun 1993; 190: 154-61.
    • (1993) Biochem Biophys Res Commun , vol.190 , pp. 154-161
    • Kawaguchi, Y.1    Harigai, M.2    Suzuki, K.3
  • 77
    • 0031880752 scopus 로고    scopus 로고
    • Enhanced interleukin 6 production by cultured fibroblasts from patients with systemic sclerosis in response to platelet derived growth factor
    • TAKEMURA H, SUZUKI H, FUJISAWA H et al.: Enhanced interleukin 6 production by cultured fibroblasts from patients with systemic sclerosis in response to platelet derived growth factor. J Rheumatol 1998; 25: 1534-9.
    • (1998) J Rheumatol , vol.25 , pp. 1534-1539
    • Takemura, H.1    Suzuki, H.2    Fujisawa, H.3
  • 78
    • 78651068822 scopus 로고    scopus 로고
    • Toll-like receptor 3 up regulation by type I interferon in healthy and scleroderma dermal fibroblasts
    • AGARWAL SK, WU M, LIVINGSTON CK et al.: Toll-like receptor 3 up regulation by type I interferon in healthy and scleroderma dermal fibroblasts. Arthritis Res Ther 2011; 13: R3.
    • (2011) Arthritis Res Ther , vol.13
    • Agarwal, S.K.1    Wu, M.2    Livingston, C.K.3
  • 79
    • 0033020912 scopus 로고    scopus 로고
    • Fibroblast proliferation by bleomycin stimulated peripheral blood mononuclear cell factors
    • YAMAMOTO T, KATAYAMA I, NISHIOKA K: Fibroblast proliferation by bleomycin stimulated peripheral blood mononuclear cell factors. J Rheumatol 1999; 26: 609-15.
    • (1999) J Rheumatol , vol.26 , pp. 609-615
    • Yamamoto, T.1    Katayama, I.2    Nishioka, K.3
  • 80
    • 45949089317 scopus 로고    scopus 로고
    • Pivotal advance: Th-1 cytokines inhibit, and th-2 cytokines promote fibrocyte differentiation
    • SHAO DD, SURESH R, VAKIL V, GOMER RH, PILLING D: Pivotal advance: Th-1 cytokines inhibit, and th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol 2008; 83: 1323-33.
    • (2008) J Leukoc Biol , vol.83 , pp. 1323-1333
    • Shao, D.D.1    Suresh, R.2    Vakil, V.3    Gomer, R.H.4    Pilling, D.5
  • 81
    • 33746896971 scopus 로고    scopus 로고
    • Costimulation blockade and its possible future use in clinical transplantation
    • SNANOUDJ R, de PRÉNEUF H, CRÉPUT C et al.: Costimulation blockade and its possible future use in clinical transplantation. Transpl Int 2006; 19: 693-704.
    • (2006) Transpl Int , vol.19 , pp. 693-704
    • Snanoudj, R.1    De Préneuf, H.2    Créput, C.3
  • 82
    • 55849109623 scopus 로고    scopus 로고
    • A CD40-CD154 interaction in tissue fibrosis
    • KAWAI M, MASUDA A, KUWANA M: A CD40-CD154 interaction in tissue fibrosis. Arthritis Rheum 2008; 58: 3562-73.
    • (2008) Arthritis Rheum , vol.58 , pp. 3562-3573
    • Kawai, M.1    Masuda, A.2    Kuwana, M.3
  • 83
    • 0242271835 scopus 로고    scopus 로고
    • Increased CD40 expression in skin fibroblasts from patients with systemic sclerosis (SSc): Role of CD40-CD154 in the phenotype of SSc fibroblasts
    • FUKASAWA C, KAWAGUCHI Y, HARIGAI M et al.: Increased CD40 expression in skin fibroblasts from patients with systemic sclerosis (SSc): Role of CD40-CD154 in the phenotype of SSc fibroblasts. Eur J Immunol 2003; 33: 2792-800.
    • (2003) Eur J Immunol , vol.33 , pp. 2792-2800
    • Fukasawa, C.1    Kawaguchi, Y.2    Harigai, M.3
  • 84
    • 0029930901 scopus 로고    scopus 로고
    • IL- 6-soluble IL-6 receptor complex inhibits the proliferation of dermal fibroblasts
    • MIHARA M, MORIYA Y, OHSUGI Y: IL- 6-soluble IL-6 receptor complex inhibits the proliferation of dermal fibroblasts. Int J Immunopharmacol 1996; 18: 89-94.
    • (1996) Int J Immunopharmacol , vol.18 , pp. 89-94
    • Mihara, M.1    Moriya, Y.2    Ohsugi, Y.3
  • 85
    • 84869741998 scopus 로고    scopus 로고
    • Antifibrotic effects of roscovitine in normal and scleroderma fibroblasts
    • STEINMAN RA, ROBINSON AR, FEGHALIBOSTWICK CA: Antifibrotic effects of roscovitine in normal and scleroderma fibroblasts. PLoS One 2012; 7: e48560.
    • (2012) PLoS One , vol.7
    • Steinman, R.A.1    Robinson, A.R.2    Feghalibostwick, C.A.3
  • 86
    • 9644258488 scopus 로고    scopus 로고
    • Cytokine and chemokine levels in systemic sclerosis: Relationship with cutaneous and internal organ involvement
    • SCALA E, PALLOTTA S, FREZZOLINI A et al.: Cytokine and chemokine levels in systemic sclerosis: Relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004; 138: 540-6.
    • (2004) Clin Exp Immunol , vol.138 , pp. 540-546
    • Scala, E.1    Pallotta, S.2    Frezzolini, A.3
  • 87
    • 0032746822 scopus 로고    scopus 로고
    • Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis
    • HASEGAWA M, SATO S, IHN H, TAKEHARA K: Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology 1999; 38: 612-7.
    • (1999) Rheumatology , vol.38 , pp. 612-617
    • Hasegawa, M.1    Sato, S.2    Ihn, H.3    Takehara, K.4
  • 88
    • 0029913252 scopus 로고    scopus 로고
    • Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor ß1
    • GIACOMELLI R, CIPRIANI P, DANESE C et al.: Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor ß1. J Rheumatol 1996; 23: 294-6.
    • (1996) J Rheumatol , vol.23 , pp. 294-296
    • Giacomelli, R.1    Cipriani, P.2    Danese, C.3
  • 89
    • 0028596014 scopus 로고
    • Augmented interleukin-6 secretion in collagenstimulated peripheral blood mononuclear cells from patients with systemic sclerosis
    • GURRAM M, PAHWA S, FRIERI M: Augmented interleukin-6 secretion in collagenstimulated peripheral blood mononuclear cells from patients with systemic sclerosis. Ann Allergy 1994; 73: 493-6.
    • (1994) Ann Allergy , vol.73 , pp. 493-496
    • Gurram, M.1    Pahwa, S.2    Frieri, M.3
  • 90
    • 0032869964 scopus 로고    scopus 로고
    • Investigation of the alveolar macrophages and T lymphocytes in 15 patients with systemic sclerosis
    • CZIRJÁK L, KONCZ A, VARGA I, DÉVÉNYI K, KUMÁNOVICS G, SZüCS G: Investigation of the alveolar macrophages and T lymphocytes in 15 patients with systemic sclerosis. Clin Rheumatol 1999; 18: 357-63.
    • (1999) Clin Rheumatol , vol.18 , pp. 357-363
    • Czirják, L.1    Koncz, A.2    Varga, I.3    Dévényi, K.4    Kumánovics, G.5    Szücs, G.6
  • 91
    • 84873832733 scopus 로고    scopus 로고
    • Tumor necrosis factor-costimulated T lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts
    • HüGLE T, O'REILLY S, SIMPSON R et al.: Tumor necrosis factor-costimulated T lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts. Arthritis Rheum 2013; 65: 481-91.
    • (2013) Arthritis Rheum , vol.65 , pp. 481-491
    • Hügle, T.1    O'reilly, S.2    Simpson, R.3
  • 92
    • 0028347997 scopus 로고
    • Interleukin 6 secretion by monocytes and alveolar macrophages in systemic sclerosis with lung involvement
    • CRESTANI B, SETA N, De BANDT M et al.: Interleukin 6 secretion by monocytes and alveolar macrophages in systemic sclerosis with lung involvement. Am J Respir Crit Care Med 1994; 149: 1260-5.
    • (1994) Am J Respir Crit Care Med , vol.149 , pp. 1260-1265
    • Crestani, B.1    Seta, N.2    De Bandt, M.3
  • 93
    • 27744604032 scopus 로고    scopus 로고
    • Abnormal natural killer cell function in systemic sclerosis: Altered cytokine production and defective killing activity
    • HORIKAWA M, HASEGAWA M, KOMURA K et al.: Abnormal natural killer cell function in systemic sclerosis: Altered cytokine production and defective killing activity. J Invest Dermatol 2005; 125: 731-7.
    • (2005) J Invest Dermatol , vol.125 , pp. 731-737
    • Horikawa, M.1    Hasegawa, M.2    Komura, K.3
  • 94
  • 95
    • 77955452418 scopus 로고    scopus 로고
    • Distinct evolution of TLR-mediated dendritic cell cytokine secretion in patients with limited and diffuse cutaneous systemic sclerosis
    • Van BON L, POPA C, HUIJBENS R et al.: Distinct evolution of TLR-mediated dendritic cell cytokine secretion in patients with limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2010; 69: 1539-47.
    • (2010) Ann Rheum Dis , vol.69 , pp. 1539-1547
    • Van Bon, L.1    Popa, C.2    Huijbens, R.3
  • 96
    • 38449105044 scopus 로고    scopus 로고
    • Nerve growth factor promotes TLR4 signaling-induced maturation of human dendritic cells in vitro through inducible p75NTR
    • JIANG Y, CHEN G, ZHANG Y, LU L, LIU S, CAO X: Nerve growth factor promotes TLR4 signaling-induced maturation of human dendritic cells in vitro through inducible p75NTR. Journal of Immunology 2007; 179: 6297-304.
    • (2007) Journal of Immunology , vol.179 , pp. 6297-6304
    • Jiang, Y.1    Chen, G.2    Zhang, Y.3    Lu, L.4    Liu, S.5    Cao, X.6
  • 97
    • 78751704435 scopus 로고    scopus 로고
    • Endothelial activation and apoptosis mediated by neutrophil- dependent interleukin 6 trans-signaling: A novel target for systemic sclerosis?
    • BARNES TC, SPILLER DG, ANDERSON ME, EDWARDS SW, MOOTS RJ: Endothelial activation and apoptosis mediated by neutrophil- dependent interleukin 6 trans-signaling: A novel target for systemic sclerosis?. Ann Rheum Dis 2011; 70: 366-72.
    • (2011) Ann Rheum Dis , vol.70 , pp. 366-372
    • Barnes, T.C.1    Spiller, D.G.2    Anderson, M.E.3    Edwards, S.W.4    Moots, R.J.5
  • 98
    • 36048960425 scopus 로고    scopus 로고
    • The nuclear autoantigen CENP-B displays cytokine-like activities toward vascular smooth muscle cells
    • ROBITAILLE G, HÉNAULT J, CHRISTIN M-, SENÉCAL J-, RAYMOND Y: The nuclear autoantigen CENP-B displays cytokine-like activities toward vascular smooth muscle cells. Arthritis Rheum 2007; 56: 3814-26.
    • (2007) Arthritis Rheum , vol.56 , pp. 3814-3826
    • Robitaille, G.1    Hénault, J.2    Christin, M.3    Senécal, J.4    Raymond, Y.5
  • 99
    • 0034659754 scopus 로고    scopus 로고
    • Analysis of soluble and cell surface factors regulating anti-DNA topoisomerase I autoantibody production demonstrates synergy between Th1 and Th2 autoreactive T cells
    • KUWANA M, MEDSGER TA Jr, WRIGHT TM: Analysis of soluble and cell surface factors regulating anti-DNA topoisomerase I autoantibody production demonstrates synergy between Th1 and Th2 autoreactive T cells. J Immunol 2000; 164: 6138-46.
    • (2000) J Immunol , vol.164 , pp. 6138-6146
    • Kuwana, M.1    Medsger Jr., T.A.2    Wright, T.M.3
  • 100
    • 0026536879 scopus 로고
    • Enhanced expression of high-affinity interleukin-2 receptors in scleroderma: Possible role for IL-6
    • KAHALEH MB, YIN T: Enhanced expression of high-affinity interleukin-2 receptors in scleroderma: Possible role for IL-6. Clin Immunol Immunopathol 1992; 62: 97-102.
    • (1992) Clin Immunol Immunopathol , vol.62 , pp. 97-102
    • Kahaleh, M.B.1    Yin, T.2
  • 101
    • 35348902738 scopus 로고    scopus 로고
    • T cells expressing allograft inflammatory factor 1 display increased chemotaxis and induce a profibrotic phenotype in normal fibroblasts in vitro
    • Del GALDO F, JIMÉNEZ SA: T cells expressing allograft inflammatory factor 1 display increased chemotaxis and induce a profibrotic phenotype in normal fibroblasts in vitro. Arthritis Rheum 2007; 56: 3478-88.
    • (2007) Arthritis Rheum , vol.56 , pp. 3478-3488
    • Del Galdo, F.1    Jiménez, S.A.2
  • 102
    • 0033673989 scopus 로고    scopus 로고
    • Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis
    • SATO S, HANAKAWA H, HASEGAWA M et al.: Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis. J Rheumatol 2000; 27: 2838-42.
    • (2000) J Rheumatol , vol.27 , pp. 2838-2842
    • Sato, S.1    Hanakawa, H.2    Hasegawa, M.3
  • 103
    • 31044440282 scopus 로고    scopus 로고
    • Elevated serum BAFF levels in patients with systemic sclerosis: Enhanced BAFF signaling in systemic sclerosis B lymphocytes
    • MATSUSHITA T, HASEGAWA M, YANABA K, KODERA M, TAKEHARA K, SATO S: Elevated serum BAFF levels in patients with systemic sclerosis: Enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006; 54: 192-201.
    • (2006) Arthritis Rheum , vol.54 , pp. 192-201
    • Matsushita, T.1    Hasegawa, M.2    Yanaba, K.3    Kodera, M.4    Takehara, K.5    Sato, S.6
  • 104
    • 83255164768 scopus 로고    scopus 로고
    • Functional disturbance of the stress-adaptation system in patients with scleroderma
    • MATSUURA E, OHTA A, SUEMATSU R et al.: Functional disturbance of the stress-adaptation system in patients with scleroderma. Modern Rheumatology 2011; 21: 397-405.
    • (2011) Modern Rheumatology , vol.21 , pp. 397-405
    • Matsuura, E.1    Ohta, A.2    Suematsu, R.3
  • 105
    • 67650114978 scopus 로고    scopus 로고
    • The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes
    • RADSTAKE TR, van BON L, BROEN J et al.: The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes.PLoS One 2009; 4: e5903.
    • (2009) PLoS One , vol.4
    • Radstake, T.R.1    Van Bon, L.2    Broen, J.3
  • 106
    • 32144454167 scopus 로고    scopus 로고
    • Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: Association of interleukin 12 elevation with spontaneous regression of skin sclerosis
    • MATSUSHITA T, HASEGAWA M, HAMAGUCHI Y, TAKEHARA K, SATO S: Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: Association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 2006; 33: 275-84.
    • (2006) J Rheumatol , vol.33 , pp. 275-284
    • Matsushita, T.1    Hasegawa, M.2    Hamaguchi, Y.3    Takehara, K.4    Sato, S.5
  • 107
    • 6544229063 scopus 로고    scopus 로고
    • Cyclosporin A and iloprost treatment of systemic sclerosis: Clinical results and interleukin- 6 serum changes after 12 months of therapy
    • FILACI G, CUTOLO M, SCUDELETTI M et al.: Cyclosporin A and iloprost treatment of systemic sclerosis: Clinical results and interleukin- 6 serum changes after 12 months of therapy. Rheumatology 1999; 38: 992-6.
    • (1999) Rheumatology , vol.38 , pp. 992-996
    • Filaci, G.1    Cutolo, M.2    Scudeletti, M.3
  • 108
    • 0029298282 scopus 로고
    • Serum interleukin-6 level in patients with systemic sclerosis: lack of correlation with aminoterminal propeptide of type III procollagen
    • KUCHARZ EJ, JONDERKO G, RUBISZBRZEZINSKA J, BRZEZINSKA-WCISLO L: Serum interleukin-6 level in patients with systemic sclerosis: lack of correlation with aminoterminal propeptide of type III procollagen. Clin Rheumatol 1995; 14: 380-1.
    • (1995) Clin Rheumatol , vol.14 , pp. 380-381
    • Kucharz, E.J.1    Jonderko, G.2    Rubiszbrzezinska, J.3    Brzezinska-Wcislo, L.4
  • 109
    • 75649105070 scopus 로고    scopus 로고
    • Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations
    • GOURH P, ARNETT FC, ASSASSI S et al.: Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 2009; 11: R147.
    • (2009) Arthritis Res Ther , vol.11
    • Gourh, P.1    Arnett, F.C.2    Assassi, S.3
  • 110
    • 73249114944 scopus 로고    scopus 로고
    • Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis
    • BEIRNE P, PANTELIDIS P, CHARLES P et al.: Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis. Eur Respir J 2009; 34: 1376-82.
    • (2009) Eur Respir J , vol.34 , pp. 1376-1382
    • Beirne, P.1    Pantelidis, P.2    Charles, P.3
  • 111
    • 0031911610 scopus 로고    scopus 로고
    • Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis
    • HASEGAWA M, SATO S, FUJIMOTO M, IHN H, KIKUCHI K, TAKEHARA K: Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 1998; 25: 308-13.
    • (1998) J Rheumatol , vol.25 , pp. 308-313
    • Hasegawa, M.1    Sato, S.2    Fujimoto, M.3    Ihn, H.4    Kikuchi, K.5    Takehara, K.6
  • 112
    • 79955802032 scopus 로고    scopus 로고
    • An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis
    • CODULLO V, BALDWIN HM, SINGH MD et al.: An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis. Ann Rheum Dis 2011; 70: 1115-21.
    • (2011) Ann Rheum Dis , vol.70 , pp. 1115-1121
    • Codullo, V.1    Baldwin, H.M.2    Singh, M.D.3
  • 114
    • 34047268711 scopus 로고    scopus 로고
    • Collagen degradation products and proinflammatory cytokines in systemic and localized scleroderma
    • BECVÁr R, HULEJOVÁ H, BRAUN M, ŠTORK J: Collagen degradation products and proinflammatory cytokines in systemic and localized scleroderma. Folia Biol 2007; 53: 66-8.
    • (2007) Folia Biol , vol.53 , pp. 66-68
    • Becvár, R.1    Hulejová, H.2    Braun, M.3    Štork, J.4
  • 115
    • 56349089937 scopus 로고    scopus 로고
    • The impact of systemic sclerosis on arterial wall stiffness parameters and endothelial function
    • CYPIENE A, LAUCEVICIUS A, VENALIS A et al.: The impact of systemic sclerosis on arterial wall stiffness parameters and endothelial function. Clin Rheumatol 2008; 27: 1517-22.
    • (2008) Clin Rheumatol , vol.27 , pp. 1517-1522
    • Cypiene, A.1    Laucevicius, A.2    Venalis, A.3
  • 116
    • 43749097225 scopus 로고    scopus 로고
    • Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors
    • HETTEMA ME, ZHANG D, de LEEUW K et al.: Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors. Arthritis Res Ther 2008; 10:R49.
    • (2008) Arthritis Res Ther , vol.10
    • Hettema, M.E.1    Zhang, D.2    de Leeuw, K.3
  • 117
    • 81555215666 scopus 로고    scopus 로고
    • Skin autofluorescence, as marker of accumulation of advanced glycation end products and of cumulative metabolic stress, is not increased in patients with systemic sclerosis
    • HETTEMA ME, BOOTSMA H, GRAAFF R, de VRIES R, KALLENBERG CG, SMIT AJ: Skin autofluorescence, as marker of accumulation of advanced glycation end products and of cumulative metabolic stress, is not increased in patients with systemic sclerosis. Int J Rheumatol 2011; 2011: 417-813.
    • (2011) Int J Rheumatol , vol.2011 , pp. 417-813
    • Hettema, M.E.1    Bootsma, H.2    Graaff, R.3    De Vries, R.4    Kallenberg, C.G.5    Smit, A.J.6
  • 118
    • 33748576596 scopus 로고    scopus 로고
    • Evaluation of cardiac laboratory markers in patients with systemic sclerosis
    • MONTAGNANA M, LIPPI G, VOLPE A et al.: Evaluation of cardiac laboratory markers in patients with systemic sclerosis. Clin Biochem 2006; 39: 913-7.
    • (2006) Clin Biochem , vol.39 , pp. 913-917
    • Montagnana, M.1    Lippi, G.2    Volpe, A.3
  • 119
    • 0027426209 scopus 로고
    • Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon
    • BLANN AD, ILLINGWORTH K, JAYSON MIV: Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. J Rheumatol 1993; 20: 1325-30.
    • (1993) J Rheumatol , vol.20 , pp. 1325-1330
    • Blann, A.D.1    Illingworth, K.2    Jayson, M.I.V.3
  • 120
    • 52649117122 scopus 로고    scopus 로고
    • Increased serum fractalkine in systematic sclerosis. down-regulation by prostaglandin E1
    • SICINSKA J, GORSKA E, CICHA M et al.: Increased serum fractalkine in systematic sclerosis. down-regulation by prostaglandin E1. Clin Exp Rheumatol 2008; 26: 527-33.
    • (2008) Clin Exp Rheumatol , vol.26 , pp. 527-533
    • Sicinska, J.1    Gorska, E.2    Cicha, M.3
  • 121
    • 33746791907 scopus 로고    scopus 로고
    • Clinical associations of C-reactive protein in systemic sclerosis
    • ALEKPEROV RT, BARANOV AA, ABAITOVA NE: Clinical associations of C-reactive protein in systemic sclerosis. Ter Arkh 2006; 78: 30-5.
    • (2006) Ter Arkh , vol.78 , pp. 30-35
    • Alekperov, R.T.1    Baranov, A.A.2    Abaitova, N.E.3
  • 123
    • 84881361943 scopus 로고    scopus 로고
    • C-reactive protein predictsthe long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis
    • February 11 [Epub ahead of print]
    • LIU X, MAYES MD, PHD CP et al.: C-reactive protein predictsthe long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis. Arthritis Care Res (Hoboken) February 11, 2013 [Epub ahead of print].
    • (2013) Arthritis Care Res (Hoboken)
    • Liu, X.1    Mayes, M.D.2    Phd, C.P.3
  • 124
    • 84877910237 scopus 로고    scopus 로고
    • Carbohydrate-deficient transferrin depends on disease activity in rheumatoid arthritis and systemic sclerosis
    • February 5, [Epub ahead of print]
    • GRUSZEWSKA E, CHLU.DZINSKA A, CHROSTEK L et al.: Carbohydrate-deficient transferrin depends on disease activity in rheumatoid arthritis and systemic sclerosis. Scand J Rheumatol February 5, 2013 [Epub ahead of print].
    • (2013) Scand J Rheumatol
    • Gruszewska, E.1    Chlu Dzinska, A.2    Chrostek, L.3
  • 125
    • 0035465473 scopus 로고    scopus 로고
    • Interleukin- 2 and interleukin-6 in serum as markers of disease progression in systemic sclerosis
    • LIS AD, BRZEZINSKA-WCISLO LA: Interleukin- 2 and interleukin-6 in serum as markers of disease progression in systemic sclerosis. Pol Merkur Lekarski 2001; 11: 206-9.
    • (2001) Pol Merkur Lekarski , vol.11 , pp. 206-209
    • Lis, A.D.1    Brzezinska-Wcislo, L.A.2
  • 126
    • 0028949892 scopus 로고
    • Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders
    • STUART RA, LITTLEWOOD AJ, MADDISON PJ, HALL ND: Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders. Clin Exp Rheumatol 1995; 13: 17-22.
    • (1995) Clin Exp Rheumatol , vol.13 , pp. 17-22
    • Stuart, R.A.1    Littlewood, A.J.2    Maddison, P.J.3    Hall, N.D.4
  • 127
    • 0032106005 scopus 로고    scopus 로고
    • The interleukin-1, interleukin-2, interleukin-6 and tumors necrosis factor alpha serological levels in localized and systemic sclerosis
    • ALECU M, GELERIU L, COMAN G, GALATESCU L: The interleukin-1, interleukin-2, interleukin-6 and tumors necrosis factor alpha serological levels in localized and systemic sclerosis. Rom J Intern Med 1998; 36: 251-9.
    • (1998) Rom J Intern Med , vol.36 , pp. 251-259
    • Alecu, M.1    Geleriu, L.2    Coman, G.3    Galatescu, L.4
  • 128
    • 0029670244 scopus 로고    scopus 로고
    • Serum cytokine and anti-Fc?R autoantibody measurements in patients with systemic sclerosis
    • SZEGEDI A, CZIRJÁK L, UNKELESS JC, BOROS P: Serum cytokine and anti-Fc?R autoantibody measurements in patients with systemic sclerosis. Acta Derm Venereol 1996; 76: 21-3.
    • (1996) Acta Derm Venereol , vol.76 , pp. 21-23
    • Szegedi, A.1    Czirják, L.2    Unkeless, J.C.3    Boros, P.4
  • 129
    • 18644363395 scopus 로고    scopus 로고
    • Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis
    • NAGY Z, CZIRJÁK L: Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis. Clin Exp Rheumatol 2005; 23: 165-72.
    • (2005) Clin Exp Rheumatol , vol.23 , pp. 165-172
    • Nagy, Z.1    Czirják, L.2
  • 130
    • 13244272290 scopus 로고    scopus 로고
    • Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1ß, and tumour necrosis factor a in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis
    • HUSSEIN MR, HASSAN HI, HOFNY ERM et al.: Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1ß, and tumour necrosis factor a in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis. J Clin Pathol 2005; 58: 178-84.
    • (2005) J Clin Pathol , vol.58 , pp. 178-184
    • Hussein, M.R.1    Hassan, H.I.2    Hofny, E.R.M.3
  • 131
    • 77956203111 scopus 로고    scopus 로고
    • Serum interleukin-6 level is reflected in elevated high-sensitivity C-reactive protein level in patients with systemic sclerosis
    • OHTSUKA T: Serum interleukin-6 level is reflected in elevated high-sensitivity C-reactive protein level in patients with systemic sclerosis. J Dermatol 2010; 37: 801-6.
    • (2010) J Dermatol , vol.37 , pp. 801-806
    • Ohtsuka, T.1
  • 132
    • 42449121505 scopus 로고    scopus 로고
    • Platelet activation in patients with systemic scleroderma - pattern and significance
    • AGACHE I, RADOI M, DUCA L: Platelet activation in patients with systemic scleroderma - pattern and significance. Rom J Intern Med 2007; 45: 183-91.
    • (2007) Rom J Intern Med , vol.45 , pp. 183-191
    • Agache, I.1    Radoi, M.2    Duca, L.3
  • 133
    • 38949172371 scopus 로고    scopus 로고
    • Relation between elevated high-sensitivity C-reactive protein and antimitochondria antibody in patients with systemic sclerosis
    • OHTSUKA T: Relation between elevated high-sensitivity C-reactive protein and antimitochondria antibody in patients with systemic sclerosis. J Dermatol 2008; 35: 70-5.
    • (2008) J Dermatol , vol.35 , pp. 70-75
    • Ohtsuka, T.1
  • 134
    • 79954450466 scopus 로고    scopus 로고
    • Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis
    • HASEGAWA M, FUJIMOTO M, MATSUSHITA T, HAMAGUCHI Y, TAKEHARA K, SATO S: Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol 2011; 30: 231-7.
    • (2011) Clin Rheumatol , vol.30 , pp. 231-237
    • Hasegawa, M.1    Fujimoto, M.2    Matsushita, T.3    Hamaguchi, Y.4    Takehara, K.5    Sato, S.6
  • 135
    • 25444471513 scopus 로고    scopus 로고
    • Clinical correlations of potential activity markers in systemic sclerosis
    • BECVÁR R, STORK J, PESÁKOVÁ V et al.: Clinical correlations of potential activity markers in systemic sclerosis. Ann N Y Acad Sci 2005; 1051: 404-12.
    • (2005) Ann N Y Acad Sci , vol.1051 , pp. 404-412
    • Becvár, R.1    Stork, J.2    Pesáková, V.3
  • 136
    • 0034856397 scopus 로고    scopus 로고
    • Serum levels of interleukin-6 and interleukin- 10 correlate with total skin thickness score in patients with systemic sclerosis
    • SATO S, HASEGAWA M, TAKEHARA K: Serum levels of interleukin-6 and interleukin- 10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001; 27: 140-6.
    • (2001) J Dermatol Sci , vol.27 , pp. 140-146
    • Sato, S.1    Hasegawa, M.2    Takehara, K.3
  • 137
    • 0030803853 scopus 로고    scopus 로고
    • Serum levels of soluble IL-2 receptor, soluble ICAM-1, TNF-alpha, interleukin-4 and interleukin-6 in scleroderma
    • BRUNS M, HAUSTEIN UF, HOFMANN C, HERRMANN K: Serum levels of soluble IL-2 receptor, soluble ICAM-1, TNF-alpha, interleukin-4 and interleukin-6 in scleroderma. J Eur Acad Dermatol Venereol 1997; 8: 222-8.
    • (1997) J Eur Acad Dermatol Venereol , vol.8 , pp. 222-228
    • Bruns, M.1    Haustein, U.F.2    Hofmann, C.3    Herrmann, K.4
  • 138
    • 0026601232 scopus 로고
    • Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma
    • NEEDLEMAN BW, WIGLEY FM, STAIR RW: Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 1992; 35: 67-72.
    • (1992) Arthritis Rheum , vol.35 , pp. 67-72
    • Needleman, B.W.1    Wigley, F.M.2    Stair, R.W.3
  • 139
    • 42449111699 scopus 로고    scopus 로고
    • A pilot study of subclinical coronary atherosclerosis in systemic sclerosis: Coronary artery calcification in cases and controls
    • KHURMA V, MEYER C, PARK GS et al.: A pilot study of subclinical coronary atherosclerosis in systemic sclerosis: Coronary artery calcification in cases and controls. Arthritis Rheum 2008; 59: 591-7.
    • (2008) Arthritis Rheum , vol.59 , pp. 591-597
    • Khurma, V.1    Meyer, C.2    Park, G.S.3
  • 140
    • 42649146185 scopus 로고    scopus 로고
    • Cytokine concentrations in exhaled breath condensates in systemic sclerosis
    • EDMÉ JL, TELLART AS, LAUNAY D et al.: Cytokine concentrations in exhaled breath condensates in systemic sclerosis. Inflammation Res 2008; 57: 151-6.
    • (2008) Inflammation Res , vol.57 , pp. 151-156
    • Edmé, J.L.1    Tellart, A.S.2    Launay, D.3
  • 141
    • 0027717313 scopus 로고
    • In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis, their role in early and late disease
    • KOCH AE, KRONFELD-HARRINGTON LB, SZEKANECZ Z et al.: In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis, their role in early and late disease. Pathobiology 1993; 61: 239-46.
    • (1993) Pathobiology , vol.61 , pp. 239-246
    • Koch, A.E.1    Kronfeld-Harrington, L.B.2    Szekanecz, Z.3
  • 143
    • 84871306916 scopus 로고    scopus 로고
    • Magnetic resonance imaging findings in patients with systemic scleroderma and musculoskeletal symptoms
    • SCHANZ S, HENES J, ULMER A et al.: Magnetic resonance imaging findings in patients with systemic scleroderma and musculoskeletal symptoms. Eur Radiol 2013; 23: 212-21.
    • (2013) Eur Radiol , vol.23 , pp. 212-221
    • Schanz, S.1    Henes, J.2    Ulmer, A.3
  • 144
    • 2442588462 scopus 로고    scopus 로고
    • Soluble receptors of cytokines in sera of patients with systemic sclerosis--clinical correlation
    • LIS AD, BRZEZINSKA-WCISLO LA: Soluble receptors of cytokines in sera of patients with systemic sclerosis--clinical correlation. Wiad Lek 2003; 56: 532-6.
    • (2003) Wiad Lek , vol.56 , pp. 532-536
    • Lis, A.D.1    Brzezinska-Wcislo, L.A.2
  • 145
    • 0028218523 scopus 로고
    • IL-6-anti-IL-6 autoantibody complexes with IL-6 activity in sera from some patients with systemic sclerosis
    • SUZUKI H, TAKEMURA H, YOSHIZAKI K et al.: IL-6-anti-IL-6 autoantibody complexes with IL-6 activity in sera from some patients with systemic sclerosis. J Immunol 1994; 152: 935-42.
    • (1994) J Immunol , vol.152 , pp. 935-942
    • Suzuki, H.1    Takemura, H.2    Yoshizaki, K.3
  • 146
    • 0026690770 scopus 로고
    • Anti-interleukin-6 autoantibodies in rheumatic diseases: Increased frequency in the sera of patients with systemic sclerosis
    • TAKEMURA H, SUZUKI H, YOSHIZAKI K et al.: Anti-interleukin-6 autoantibodies in rheumatic diseases: Increased frequency in the sera of patients with systemic sclerosis. Arthritis Rheum 1992; 35: 940-3.
    • (1992) Arthritis Rheum , vol.35 , pp. 940-943
    • Takemura, H.1    Suzuki, H.2    Yoshizaki, K.3
  • 147
    • 26244465904 scopus 로고    scopus 로고
    • Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis
    • De SANTIS M, BOSELLO S, La TORRE G et al.: Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res 2005; 6: 96.
    • (2005) Respir Res , vol.6 , pp. 96
    • De Santis, M.1    Bosello, S.2    La Torre, G.3
  • 148
    • 77957914450 scopus 로고    scopus 로고
    • Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury
    • PENDERGRASS SA, HAYES E, FARINA G et al.: Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS One 2010; 5: e12106.
    • (2010) PLoS One , vol.5
    • Pendergrass, S.A.1    Hayes, E.2    Farina, G.3
  • 149
    • 0037282897 scopus 로고    scopus 로고
    • Clinical features of patients with systemic sclerosis accompanied by rheumatoid arthritis
    • JINNIN M, IHN H, YAMANE K, ASANO Y, YAZAWA N, TAMAKI K: Clinical features of patients with systemic sclerosis accompanied by rheumatoid arthritis. Clin Exp Rheumatol 2003; 21: 91-4.
    • (2003) Clin Exp Rheumatol , vol.21 , pp. 91-94
    • Jinnin, M.1    Ihn, H.2    Yamane, K.3    Asano, Y.4    Yazawa, N.5    Tamaki, K.6
  • 150
    • 0035038490 scopus 로고    scopus 로고
    • Renal vascular damage in Japanese patients with systemic sclerosis
    • NISHIJIMA C, SATO S, HASEGAWA M et al.: Renal vascular damage in Japanese patients with systemic sclerosis. Rheumatology 2001; 40: 406-9.
    • (2001) Rheumatology , vol.40 , pp. 406-409
    • Nishijima, C.1    Sato, S.2    Hasegawa, M.3
  • 151
    • 27544463468 scopus 로고    scopus 로고
    • Anti-DNA topoisomerase II a autoantibodies in Japanese patients with systemic sclerosis
    • HAYAKAWA I, HASEGAWA M, TAKEHARA K, SATO S: Anti-DNA topoisomerase II a autoantibodies in Japanese patients with systemic sclerosis. Arch Dermatol Res 2005; 297: 180-3.
    • (2005) Arch Dermatol Res , vol.297 , pp. 180-183
    • Hayakawa, I.1    Hasegawa, M.2    Takehara, K.3    Sato, S.4
  • 152
    • 22844452819 scopus 로고    scopus 로고
    • Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis
    • HAYAKAWA I, HASEGAWA M, MATSUSHITA T et al.: Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis. Rheumatology 2005; 44: 873-8.
    • (2005) Rheumatology , vol.44 , pp. 873-878
    • Hayakawa, I.1    Hasegawa, M.2    Matsushita, T.3
  • 153
    • 8344262301 scopus 로고    scopus 로고
    • Rheumatoid factor isotypes and anti-agalactosyl IgG antibodies in systemic sclerosis
    • MIMURA Y, IHN H, JINNIN M et al.: Rheumatoid factor isotypes and anti-agalactosyl IgG antibodies in systemic sclerosis. Br J Dermatol 2004; 151: 803-8.
    • (2004) Br J Dermatol , vol.151 , pp. 803-808
    • Mimura, Y.1    Ihn, H.2    Jinnin, M.3
  • 156
    • 84875860763 scopus 로고    scopus 로고
    • Low Socioeconomic Status (Measured by Education) and Outcomes in Systemic Sclerosis: Data from the Canadian Scleroderma Research Group
    • MANSOUR S, BONNER A, MUANGCHAN C, HUDSON M, BARON M, POPE JE; and The Canadian Scleroderma Research Group: Low Socioeconomic Status (Measured by Education) and Outcomes in Systemic Sclerosis: Data from the Canadian Scleroderma Research Group. J Rheumatol 2013; 40: 447-54.
    • (2013) J Rheumatol , vol.40 , pp. 447-454
    • Mansour, S.1    Bonner, A.2    Muangchan, C.3    Hudson, M.4    Baron, M.5    Pope, J.E.6
  • 157
    • 0030904129 scopus 로고    scopus 로고
    • Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis
    • BOLSTER MB, LUDWICKA A, SUTHERLAND SE, STRANGE C, SILVER RM: Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 1997; 40: 743-51.
    • (1997) Arthritis Rheum , vol.40 , pp. 743-751
    • Bolster, M.B.1    Ludwicka, A.2    Sutherland, S.E.3    Strange, C.4    Silver, R.M.5
  • 158
    • 0033677566 scopus 로고    scopus 로고
    • Clinical and laboratory features of scleroderma patients with pulmonary hypertension
    • YAMANE K, IHN H, ASANO Y et al.: Clinical and laboratory features of scleroderma patients with pulmonary hypertension. Rheumatology 2000; 39: 1269-71.
    • (2000) Rheumatology , vol.39 , pp. 1269-1271
    • Yamane, K.1    Ihn, H.2    Asano, Y.3
  • 159
    • 79955555100 scopus 로고    scopus 로고
    • Systemic sclerosis is an independent risk factor for increased coronary artery calcium deposition
    • MOK MY, LAU CS, CHIU SSH et al.: Systemic sclerosis is an independent risk factor for increased coronary artery calcium deposition. Arthritis Rheum 2011; 63: 1387-95.
    • (2011) Arthritis Rheum , vol.63 , pp. 1387-1395
    • Mok, M.Y.1    Lau, C.S.2    Chiu, S.S.H.3
  • 161
    • 7244232680 scopus 로고    scopus 로고
    • Autoantibodies against phosphatidylserineprothrombin complex in patients with systemic sclerosis
    • HASEGAWA M, SATO S, YANABA K, KOMURA K, YAMAZAKI M, TAKEHARA K: Autoantibodies against phosphatidylserineprothrombin complex in patients with systemic sclerosis. Ann Rheum Dis 2004; 63: 1514-7.
    • (2004) Ann Rheum Dis , vol.63 , pp. 1514-1517
    • Hasegawa, M.1    Sato, S.2    Yanaba, K.3    Komura, K.4    Yamazaki, M.5    Takehara, K.6
  • 162
    • 78651110762 scopus 로고    scopus 로고
    • Elevated serum levels of a proliferation-inducing ligand in patients with systemic sclerosis: Possible association with myositis?
    • BASSYOUNI IH, AZAB NA, El-DAKRONY EHM, FAWZI MMT, GHANOUM R, BASSYOUNI RH: Elevated serum levels of a proliferation-inducing ligand in patients with systemic sclerosis: Possible association with myositis?. Joint Bone Spine 2011; 78: 56-61.
    • (2011) Joint Bone Spine , vol.78 , pp. 56-61
    • Bassyouni, I.H.1    Azab, N.A.2    El-Dakrony, E.H.M.3    Fawzi, M.M.T.4    Ghanoum, R.5    Bassyouni, R.H.6
  • 163
    • 59149085881 scopus 로고    scopus 로고
    • Autoantibody against a protease domain of caspase-8 in patients with systemic sclerosis
    • YAMAOKA T, OGAWA F, MUROI E et al.: Autoantibody against a protease domain of caspase-8 in patients with systemic sclerosis. Clin Exp Rheumatol 2008; 26: 998-1004.
    • (2008) Clin Exp Rheumatol , vol.26 , pp. 998-1004
    • Yamaoka, T.1    Ogawa, F.2    Muroi, E.3
  • 164
    • 25444471513 scopus 로고    scopus 로고
    • Clinical correlations of potential activity markers in systemic sclerosis
    • BECVÁR R, STORK J, PESÁKOVÁ V et al.: Clinical correlations of potential activity markers in systemic sclerosis. Ann N Y Acad Sci 2005; 1051: 404-12.
    • (2005) Ann N Y Acad Sci , vol.1051 , pp. 404-412
    • Becvár, R.1    Stork, J.2    Pesáková, V.3
  • 165
    • 42249103262 scopus 로고    scopus 로고
    • Elevation of IgG levels is a serological indicator for pulmonary fibrosis in systemic sclerosis with antitopoisomerase I antibodies and those with anticentromere antibody
    • KOMURA K, YANABA K, OGAWA F, SHIMIZU K, TAKEHARA K, SATO S: Elevation of IgG levels is a serological indicator for pulmonary fibrosis in systemic sclerosis with antitopoisomerase I antibodies and those with anticentromere antibody. Clin Exp Dermatol 2008; 33: 329-32.
    • (2008) Clin Exp Dermatol , vol.33 , pp. 329-332
    • Komura, K.1    Yanaba, K.2    Ogawa, F.3    Shimizu, K.4    Takehara, K.5    Sato, S.6
  • 166
    • 84875861264 scopus 로고    scopus 로고
    • Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis
    • De LAURETIS A, SESTINI P, PANTELIDIS P et al.: Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis. J Rheumatol 2013; 40: 435-46.
    • (2013) J Rheumatol , vol.40 , pp. 435-446
    • De Lauretis, A.1    Sestini, P.2    Pantelidis, P.3
  • 167
    • 84859217173 scopus 로고    scopus 로고
    • Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis
    • TOMCíK M, ARIMA K, HULEJOVÁ H et al.: Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis. Cytokine 2012; 58: 165-8.
    • (2012) Cytokine , vol.58 , pp. 165-168
    • Tomcík, M.1    Arima, K.2    Hulejová, H.3
  • 168
    • 0027503082 scopus 로고
    • Cell surface expression of lysosome-associated membrane proteins (LAMPs) in scleroderma: relationship of lamp2 to disease duration, anti-Sc170 antibodies, serum interleukin-8, and soluble interleukin-2 receptor levels
    • HOLCOMBE RF, BAETHGE BA, STEWART RM et al.: Cell surface expression of lysosome-associated membrane proteins (LAMPs) in scleroderma: relationship of lamp2 to disease duration, anti-Sc170 antibodies, serum interleukin-8, and soluble interleukin-2 receptor levels. Clin Immunol Immunopathol 1993; 67: 31-9.
    • (1993) Clin Immunol Immunopathol , vol.67 , pp. 31-39
    • Holcombe, R.F.1    Baethge, B.A.2    Stewart, R.M.3
  • 169
    • 77953484773 scopus 로고    scopus 로고
    • Construct validity evaluation of the European scleroderma study group activity index, and investigation of possible new disease activity markers in systemic sclerosis
    • MINIER T, NAGY Z, BÁLINT Z et al.: Construct validity evaluation of the European scleroderma study group activity index, and investigation of possible new disease activity markers in systemic sclerosis. Rheumatology 2010; 49: 1133-45.
    • (2010) Rheumatology , vol.49 , pp. 1133-1145
    • Minier, T.1    Nagy, Z.2    Bálint, Z.3
  • 170
    • 67650523691 scopus 로고    scopus 로고
    • Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis
    • SCHOINDRE Y, MEUNE C, DINH-XUAN AT, AVOUAC J, KAHAN A, ALLANORE Y: Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis. J Rheumatol 2009; 36: 1481-5.
    • (2009) J Rheumatol , vol.36 , pp. 1481-1485
    • Schoindre, Y.1    Meune, C.2    Dinh-Xuan, A.T.3    Avouac, J.4    Kahan, A.5    Allanore, Y.6
  • 171
    • 0031056613 scopus 로고    scopus 로고
    • Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis
    • HASEGAWA M, FUJIMOTO M, KIKUCHI K, TAKEHARA K: Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997; 24: 328-32.
    • (1997) J Rheumatol , vol.24 , pp. 328-332
    • Hasegawa, M.1    Fujimoto, M.2    Kikuchi, K.3    Takehara, K.4
  • 172
    • 1542410396 scopus 로고    scopus 로고
    • Elevated circulating CD40L concentrations in patients with systemic sclerosis
    • KOMURA K, SATO S, HASEGAWA M, FUJIMOTO M, TAKEHARA K: Elevated circulating CD40L concentrations in patients with systemic sclerosis. J Rheumatol 2004; 31: 514-9.
    • (2004) J Rheumatol , vol.31 , pp. 514-519
    • Komura, K.1    Sato, S.2    Hasegawa, M.3    Fujimoto, M.4    Takehara, K.5
  • 173
    • 51849160858 scopus 로고    scopus 로고
    • The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis
    • GUIDUCCI S, DISTLER JHW, JüNGEL A et al.: The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. Arthritis Rheum 2008; 58: 2845-53.
    • (2008) Arthritis Rheum , vol.58 , pp. 2845-2853
    • Guiducci, S.1    Distler, J.H.W.2    Jüngel, A.3
  • 174
    • 77649334839 scopus 로고    scopus 로고
    • Blood serum levels of amino-terminal pro-c-type natriuretic peptide in patients with systemic sclerosis
    • OLEWICZ-GAWLIK A, DANCZAK-PAZDROW-SKA A, KLAMA K et al.: Blood serum levels of amino-terminal pro-c-type natriuretic peptide in patients with systemic sclerosis. Connect Tissue Res 2010; 51: 83-7.
    • (2010) Connect Tissue Res , vol.51 , pp. 83-87
    • Olewicz-Gawlik, A.1    Danczak-Pazdrow-Ska, A.2    Klama, K.3
  • 175
    • 84856022022 scopus 로고    scopus 로고
    • Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-a treatment
    • HAPPONEN KE, SAXNE T, GEBOREK P et al.: Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-a treatment. Arthritis Res Ther 2012; 14: R15.
    • (2012) Arthritis Res Ther , vol.14
    • Happonen, K.E.1    Saxne, T.2    Geborek, P.3
  • 176
    • 12244264813 scopus 로고    scopus 로고
    • Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis
    • ALLANORE Y, BORDERIE D, LEMARÉCHAL H, CHERRUAU B, EKINDJIAN OG, KAHAN A: Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 2003; 30: 68-73.
    • (2003) J Rheumatol , vol.30 , pp. 68-73
    • Allanore, Y.1    Borderie, D.2    Lemaréchal, H.3    Cherruau, B.4    Ekindjian, O.G.5    Kahan, A.6
  • 177
    • 79959580692 scopus 로고    scopus 로고
    • Increasing levels of serum antioxidant status, total antioxidant power, in systemic sclerosis
    • OGAWA F, SHIMIZU K, MUROI E, HARA T, SATO S: Increasing levels of serum antioxidant status, total antioxidant power, in systemic sclerosis. Clin Rheumatol 2011; 30: 921-5.
    • (2011) Clin Rheumatol , vol.30 , pp. 921-925
    • Ogawa, F.1    Shimizu, K.2    Muroi, E.3    Hara, T.4    Sato, S.5
  • 178
    • 52649135593 scopus 로고    scopus 로고
    • Serum levels of heat shock protein 70, a biomarker of cellular stress, are elevated in patients with systemic sclerosis: Association with fibrosis vascular damage
    • OGAWA F, SHIMIZU K, HARA T et al.: Serum levels of heat shock protein 70, a biomarker of cellular stress, are elevated in patients with systemic sclerosis: Association with fibrosis vascular damage. Clin Exp Rheumatol 2008; 26: 659-62.
    • (2008) Clin Exp Rheumatol , vol.26 , pp. 659-662
    • Ogawa, F.1    Shimizu, K.2    Hara, T.3
  • 179
    • 84885181545 scopus 로고    scopus 로고
    • Dynamics of serum angiopoietin-2 levels correlate with efficacy of intravenous pulse cyclophosphamide therapy for interstitial lung disease associated with systemic sclerosis
    • Sep 13 [Epub ahead of print]
    • TAKAHASHI T, ASANO Y, AKAMATA K et al.: Dynamics of serum angiopoietin-2 levels correlate with efficacy of intravenous pulse cyclophosphamide therapy for interstitial lung disease associated with systemic sclerosis. Mod Rheumatol 2012 Sep 13 [Epub ahead of print].
    • (2012) Mod Rheumatol
    • Takahashi, T.1    Asano, Y.2    Akamata, K.3
  • 180
    • 77956485173 scopus 로고    scopus 로고
    • Is serum albumin a marker of malnutrition in chronic disease? the scleroderma paradigm
    • BARON M, HUDSON M, STEELE R et al.: Is serum albumin a marker of malnutrition in chronic disease? the scleroderma paradigm. J Am Coll Nutr 2010; 29: 144-51.
    • (2010) J Am Coll Nutr , vol.29 , pp. 144-151
    • Baron, M.1    Hudson, M.2    Steele, R.3
  • 181
    • 78649326513 scopus 로고    scopus 로고
    • Very low levels of vitamin D in systemic sclerosis patients
    • CARAMASCHI P, DALLA GASSA A, RUZZENENTE O et al.: Very low levels of vitamin D in systemic sclerosis patients. Clin Rheumatol 2010; 29: 1419-25.
    • (2010) Clin Rheumatol , vol.29 , pp. 1419-1425
    • Caramaschi, P.1    Dalla Gassa, A.2    Ruzzenente, O.3
  • 183
    • 84865176917 scopus 로고    scopus 로고
    • Aldolase predicts subsequent myopathy occurrence in systemic sclerosis
    • TOLÉDANO C, GAIN M, KETTANEH A et al.: Aldolase predicts subsequent myopathy occurrence in systemic sclerosis. Arthritis Res Ther 2012; 14: R152.
    • (2012) Arthritis Res Ther , vol.14
    • Tolédano, C.1    Gain, M.2    Kettaneh, A.3
  • 184
    • 2342652959 scopus 로고    scopus 로고
    • Clinical determinants of bone mass and bone ultrasonometry in patients with systemic sclerosis
    • FREDIANI B, BALDI F, FALSETTI P et al.: Clinical determinants of bone mass and bone ultrasonometry in patients with systemic sclerosis. Clin Exp Rheumatol 2004; 22: 313-8.
    • (2004) Clin Exp Rheumatol , vol.22 , pp. 313-318
    • Frediani, B.1    Baldi, F.2    Falsetti, P.3
  • 185
    • 14044254256 scopus 로고    scopus 로고
    • Aortic stiffness in systemic sclerosis is increased independently of the extent of skin involvement
    • MOYSSAKIS I, GIALAFOS E, VASSILIOU V et al.: Aortic stiffness in systemic sclerosis is increased independently of the extent of skin involvement. Rheumatology 2005; 44: 251-4.
    • (2005) Rheumatology , vol.44 , pp. 251-254
    • Moyssakis, I.1    Gialafos, E.2    Vassiliou, V.3
  • 186
    • 67449100026 scopus 로고    scopus 로고
    • Increased serum pentraxin 3 in patients with systemic sclerosis
    • IWATA Y, YOSHIZAKI A, OGAWA F et al.: Increased serum pentraxin 3 in patients with systemic sclerosis. J Rheumatol 2009; 36: 976-83.
    • (2009) J Rheumatol , vol.36 , pp. 976-983
    • Iwata, Y.1    Yoshizaki, A.2    Ogawa, F.3
  • 187
    • 34447536609 scopus 로고    scopus 로고
    • Normal circulating serum amyloid P component concentration in systemic sclerosis
    • TENNENT GA, DZIADZIO M, TRIANTAFILLIDOU E et al.: Normal circulating serum amyloid P component concentration in systemic sclerosis. Arthritis Rheum 2007; 56: 2013-7.
    • (2007) Arthritis Rheum , vol.56 , pp. 2013-2017
    • Tennent, G.A.1    Dziadzio, M.2    Triantafillidou, E.3
  • 190
    • 60149109220 scopus 로고    scopus 로고
    • Skin ulcers in systemic sclerosis: Determinants of presence and predictive factors of healing
    • ALIVERNINI S, De SANTIS M, TOLUSSO B et al.: Skin ulcers in systemic sclerosis: Determinants of presence and predictive factors of healing. J Am Acad Dermatol 2009; 60: 426-35.
    • (2009) J Am Acad Dermatol , vol.60 , pp. 426-435
    • Alivernini, S.1    De Santis, M.2    Tolusso, B.3
  • 191
    • 84883764649 scopus 로고    scopus 로고
    • Nailfold capillaroscopy abnormalities as predictors of mortality in patients with systemic sclerosis
    • KAYSER C, SEKIYAMA JY, PRóSPERO LC, CAMARGO CZ, ANDRADE LE: Nailfold capillaroscopy abnormalities as predictors of mortality in patients with systemic sclerosis. Clin Exp Rheumatol 2013; 31 (Suppl. 76): S115-S117.
    • (2013) Clin Exp Rheumatol , vol.31 , Issue.SUPPL. 76
    • Kayser, C.1    Sekiyama, J.Y.2    Próspero, L.C.3    Camargo, C.Z.4    Andrade, L.E.5
  • 192
    • 0030897920 scopus 로고    scopus 로고
    • Von willebrand factor: Increased levels are related to poor prognosis in systemic sclerosis and not to tissue autoantibodies
    • BLANN AD, SHEERAN TP, EMERY P: Von willebrand factor: Increased levels are related to poor prognosis in systemic sclerosis and not to tissue autoantibodies. Br J Biomed Sci 1997; 54: 5-9.
    • (1997) Br J Biomed Sci , vol.54 , pp. 5-9
    • Blann, A.D.1    Sheeran, T.P.2    Emery, P.3
  • 193
    • 78049421175 scopus 로고    scopus 로고
    • The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab
    • SHIMA Y, KUWAHARA Y, MUROTA H et al.: The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology 2010; 49: 2408-12.
    • (2010) Rheumatology , vol.49 , pp. 2408-2412
    • Shima, Y.1    Kuwahara, Y.2    Murota, H.3
  • 194
    • 84923345569 scopus 로고    scopus 로고
    • Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab
    • March 1 [Epub ahead of print]
    • SHIMA Y, HOSEN N, HIRANO T et al.: Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab. Mod Rheumatol 2013 March 1 [Epub ahead of print].
    • (2013) Mod Rheumatol
    • Shima, Y.1    Hosen, N.2    Hirano, T.3
  • 195
    • 77956992383 scopus 로고    scopus 로고
    • B cell depletion in diffuse progressive systemic sclerosis: Safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial
    • BOSELLO S, De SANTIS M, LAMA G et al.: B cell depletion in diffuse progressive systemic sclerosis: Safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010; 12: R54.
    • (2010) Arthritis Res Ther , vol.12
    • Bosello, S.1    De Santis, M.2    Lama, G.3
  • 196
    • 79957789715 scopus 로고    scopus 로고
    • Evaluation of the effect of bosentan treatment on proinflammatory cytokine serum levels in patients affected by systemic sclerosis
    • BELLISAI F, MOROZZI G, SCACCIA F et al.: Evaluation of the effect of bosentan treatment on proinflammatory cytokine serum levels in patients affected by systemic sclerosis. Int J Immunopathol Pharmacol 2011; 24: 261-4.
    • (2011) Int J Immunopathol Pharmacol , vol.24 , pp. 261-264
    • Bellisai, F.1    Morozzi, G.2    Scaccia, F.3
  • 197
    • 35748954048 scopus 로고    scopus 로고
    • Statins as immunomodulators in systemic sclerosis
    • ABOU-RAYA A, ABOU-RAYA S, HELMII M: Statins as immunomodulators in systemic sclerosis. Ann N Y Acad Sci 2007; 1110: 670-80.
    • (2007) Ann N Y Acad Sci , vol.1110 , pp. 670-680
    • Abou-Raya, A.1    Abou-Raya, S.2    Helmii, M.3
  • 198
    • 47349091867 scopus 로고    scopus 로고
    • Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in systemic sclerosis
    • Del PAPA N, CORTIANA M, VITALI C et al.: Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in systemic sclerosis. J Rheumatol 2008; 35: 1323-8.
    • (2008) J Rheumatol , vol.35 , pp. 1323-1328
    • Del Papa, N.1    Cortiana, M.2    Vitali, C.3
  • 200
    • 0028211614 scopus 로고
    • Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide
    • ÅKESSON A, SCHEJA A, LUNDIN A, WOLLHEIM FA: Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994; 37: 729-35.
    • (1994) Arthritis Rheum , vol.37 , pp. 729-735
    • Åkesson, A.1    Scheja, A.2    Lundin, A.3    Wollheim, F.A.4
  • 201
    • 67651173119 scopus 로고    scopus 로고
    • Cyclophosphamide: Effective in the treatment of severe cutaneous involvement in systemic sclerosis
    • de MACEDO PA, BORGES CTL, de SOUZA RBC: Cyclophosphamide: Effective in the treatment of severe cutaneous involvement in systemic sclerosis. Revista Brasileira de Reumatologia 2009; 49: 270-5.
    • (2009) Revista Brasileira de Reumatologia , vol.49 , pp. 270-275
    • de Macedo, P.A.1    Borges, C.T.L.2    de Souza, R.B.C.3
  • 202
    • 84883806077 scopus 로고    scopus 로고
    • Prolonged treatment with transcutaneous electrical nerve stimulation (TENS) modulates neuro-gastric motility and plasma levels of vasoactive intestinal peptide (VIP), motilin and interleukin-6 (IL-6) in systemic sclerosis
    • McNEARNEY TA, SALLAM HS, HUNNICUTT SE, DOSHI D, CHEN JD: Prolonged treatment with transcutaneous electrical nerve stimulation (TENS) modulates neuro-gastric motility and plasma levels of vasoactive intestinal peptide (VIP), motilin and interleukin-6 (IL-6) in systemic sclerosis. Clin Exp Rheumatol 2013; 31 (Suppl. 76): S140-S150.
    • (2013) Clin Exp Rheumatol , vol.31 , Issue.SUPPL. 76
    • McNearney, T.A.1    Sallam, H.S.2    Hunnicutt, S.E.3    Doshi, D.4    Chen, J.D.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.